Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Cancer

Treatments: Drug: EVRI (BMS-690514)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00578916

CA187-003

Details and patient eligibility

About

The purpose of this study is to determine how the human body processes and eliminates the drug (BMS-690514.

Enrollment: 17 patients

Sex: Male

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male subjects
• Body mass index (BMS) of 18 - 30 kg/m², inclusive

Exclusion criteria

• Radiation exposure from diagnostic X-rays (except dental X-rays) in the last year or from clinical trials in the last 5 years

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

17 participants in 1 patient group

1

Experimental group

Treatment:

Drug: EVRI (BMS-690514)